Blocking IL-11 Reverses Lung Scarring in IPF Mice, Study Finds

Joana Carvalho, PhD avatar

by Joana Carvalho, PhD |

Share this article:

Share article via email
PDGFA, aged IPF mouse model

Blocking the activity of interleukin-11 (IL-11) — a molecule that mediates immune and inflammatory responses — reverses tissue scarring, or fibrosis, in the lungs of mice with idiopathic pulmonary fibrosis (IPF), a study has found.

The findings of the study, “Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis,” were published in the journal Science Translational Medicine.

IPF is a chronic lung disease of unknown origin, characterized by lung tissue injury that is followed by the differentiation, or development of fibroblasts — connective tissue cells — into invasive myofibroblasts.  Those myofibroblasts produce large amounts of proteins from the extracellular matrix (ECM) — the network that surrounds and supports cells — resulting in tissue scarring and loss of lung function.

Previous studies by the same researchers found that IL-11 was highly produced by fibroblasts isolated from the lungs of IPF patients. However, at the time, the researchers were unsure of its function, or possible contribution to the disease’s development or progression.

Later studies then demonstrated that high levels of IL-11 led to tissue scarring in the heart and kidneys.

Taken together, these observations pointed toward the possibility that IL-11 might play a central role in tissue scarring in IPF.

To explore this possibility in more depth, the researchers from the MRC London Institute of Medical Sciences (LMS) and their collaborators performed a series of in vitro, or in the lab experiments using lung fibroblasts isolated from people with IPF.

As in their previous study, they found these fibroblasts produced high quantities of IL-11. However, the team also discovered that IL-11 led to the activation of genes that turned these lung fibroblasts into invasive myofibroblasts, which in turn produced large amounts of collagen and other ECM proteins.

The team forced mice lung fibroblasts to produce large quantities of IL-11 using genetic manipulation, or administered IL-11 directly to the animals. The lung fibroblasts differentiated — or became progressively more specialized — into myofibroblasts, and the animals ended up developing IPF.

However, when the scientists performed the same experiments in mice that had been genetically modified to lack a subunit of the IL-11 receptor, lung fibroblasts were unable to respond to the molecule and turn into myofibroblasts. For that reason, none of the animals developed the disease.

The researchers then decided to block the activity of IL-11 using an IL-11-neutralizing antibody. The goal was to see whether this would be sufficient to prevent or even reverse the process of tissue scarring in the lungs of mice with IPF.

Results showed that the neutralizing antibody not only prevented lung fibroblasts from turning into invasive myofibroblasts. It also reduced inflammation and reversed existing tissue scarring in the animals’ lungs, suggesting that IL-11 could be explored as a future therapeutic target of IPF.

“We found that blocking the IL-11 protein with antibodies could reverse fibrosis in a mouse model of human lung disease. This is a remarkable finding as reversing fibrosis is tough to do. We believe this holds promise for treating fibrotic lung diseases, like IPF, in patients,” Stuart Cook, head of the cardiovascular disease mechanism group at the MRC LMS, and senior author of the study, said in a press release.

“This exciting research highlights the importance of IL-11 in driving the development of fibrosis, and gives hope for a new treatment approach to halt and maybe even reverse the devastating lung scarring of IPF,” said Toby Maher, a study co-author.

“Although we have treatments to slow disease progression, we desperately need new therapies to genuinely transform outcomes for people with IPF,” Maher said.

According to Cook, the team is “planning to test our antibodies [against IL-11] in human safety trials by the end of 2020, and then start clinical trials with patients in 2021.”

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums